AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone215-988-0080
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$370,000.00
Profitability
Miscellaneous
Employees31
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable
AIM ImmunoTech (NYSE:AIM) Frequently Asked Questions
What is AIM ImmunoTech's stock symbol?
AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."
How were AIM ImmunoTech's earnings last quarter?
AIM ImmunoTech Inc. (NYSE:AIM) issued its quarterly earnings results on Thursday, August, 15th. The company reported ($1.07) earnings per share (EPS) for the quarter. The business had revenue of $0.03 million for the quarter. View AIM ImmunoTech's Earnings History.
When is AIM ImmunoTech's next earnings date?
What is the consensus analysts' recommendation for AIM ImmunoTech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AIM ImmunoTech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AIM ImmunoTech.
Has AIM ImmunoTech been receiving favorable news coverage?
Media stories about AIM stock have trended negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AIM ImmunoTech earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for AIM ImmunoTech.
Who are some of AIM ImmunoTech's key competitors?
What other stocks do shareholders of AIM ImmunoTech own?
Who are AIM ImmunoTech's key executives?
AIM ImmunoTech's management team includes the folowing people:
- Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)
- Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)
- Mr. Adam Pascale, Consultant (Age 71)
- Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)
- Ms. Ellen Lintal, Chief Accounting Officer
How do I buy shares of AIM ImmunoTech?
Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AIM ImmunoTech's stock price today?
One share of AIM stock can currently be purchased for approximately $0.57.
How big of a company is AIM ImmunoTech?
What is AIM ImmunoTech's official website?
How can I contact AIM ImmunoTech?
AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The company can be reached via phone at 215-988-0080 or via email at [email protected]
MarketBeat Community Rating for AIM ImmunoTech (NYSE AIM)
MarketBeat's community ratings are surveys of what our community members think about AIM ImmunoTech and other stocks. Vote "Outperform" if you believe AIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
